Catalyst Wire Dossier Catalyst Wire Dossier

ABC/DTG/3TC

abacavir/dolutegravir/lamivudine
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ABC/DTG/3TC, covering 2018-07-23 to 2018-07-23. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed [Phase 3]

See pricing